Panitumumab

Panitumumab
Name	Panitumumab
Tradename	Vectibix
Routes of administration	Intravenous
Class	Monoclonal antibody; epidermal growth factor receptor antagonist
Legal status	Prescription-only

Panitumumab is a fully human monoclonal antibody indicated for the treatment of certain metastatic colorectal cancers. It targets the epidermal growth factor receptor and is used in defined molecular contexts guided by genetic testing. Clinical use, dosing, and safety considerations have been informed by randomized trials, regulatory approvals, and oncology practice guidelines.

Medical uses

Panitumumab is approved for treatment of metastatic colorectal cancer after molecular stratification using assays such as those developed by Food and Drug Administration-regulated diagnostics and laboratories affiliated with universities like Johns Hopkins Hospital, Memorial Sloan Kettering Cancer Center, and Massachusetts General Hospital. It is indicated for patients with wild-type RAS genes as determined by tests comparable to platforms from Roche and Thermo Fisher Scientific, and is used both as monotherapy and in combination with cytotoxic regimens employed at cancer centers like Mayo Clinic and MD Anderson Cancer Center. Major clinical trials conducted through consortia including the National Cancer Institute cooperative groups compared panitumumab-containing regimens against comparators such as therapies from Amgen and Bristol-Myers Squibb, influencing guidelines from bodies like the European Medicines Agency and committees at the American Society of Clinical Oncology.

Mechanism of action

Panitumumab binds the extracellular domain of the epidermal growth factor receptor (EGFR), blocking ligand interactions similar to the mechanisms described in preclinical reports from institutions like Dana-Farber Cancer Institute and Cold Spring Harbor Laboratory. By inhibiting EGFR signaling cascades, it interferes with downstream pathways involving effectors studied in research at Stanford University and Harvard Medical School, including routes that converge on proliferation regulators characterized in publications from National Institutes of Health investigators. The therapeutic effect depends on tumor genotype, with resistance mechanisms involving mutations in genes identified in genome projects led by groups such as the Wellcome Trust and International Cancer Genome Consortium.

Pharmacology

Pharmacokinetic and pharmacodynamic profiles were elucidated in studies run by academic centers like University of California, San Francisco and pharmaceutical research divisions at companies such as Amgen. Panitumumab exhibits linear and target-mediated disposition consistent with other monoclonal antibodies described in texts from Oxford University Press authors; serum half-life estimates informed dosing schedules employed in multicenter trials coordinated by networks such as the European Organisation for Research and Treatment of Cancer. Interaction potential with chemotherapeutic agents used at institutions like Princess Margaret Cancer Centre and supportive care practices from Royal Marsden Hospital informed combination regimens. Biomarker-driven response correlations were explored in translational programs involving collaborations with groups like Broad Institute.

Administration and dosing

Panitumumab is administered intravenously in infusion centers at hospitals including Cleveland Clinic and outpatient oncology clinics affiliated with Guy's and St Thomas' NHS Foundation Trust. Label-recommended dosing schedules stem from pivotal trials run by cooperative groups partnering with manufacturers and regulatory reviewers at bodies like the Medicines and Healthcare products Regulatory Agency and the Food and Drug Administration. Dose adjustments for toxicity follow protocols similar to those used in practice guidelines from organizations such as the National Comprehensive Cancer Network and consensus statements from societies including the European Society for Medical Oncology.

Adverse effects

Common and serious toxicities were characterized in phase III programs sponsored by industry and academic collaborators including trial sites at University College London Hospitals and Vanderbilt University Medical Center. Dermatologic reactions, electrolyte disturbances, and infusion-related events mirror findings reported in safety reviews by panels convened at the American Association for Cancer Research meetings. Management strategies referenced in consensus guidance from groups such as the European Academy of Dermatology and Venereology and symptom-control research at St. Jude Children's Research Hospital inform clinical practice.

Contraindications and precautions

Labeling developed with input from regulatory agencies including the Food and Drug Administration and European Medicines Agency outlines contraindications and monitoring requirements adopted by oncology services at institutions like Johns Hopkins Hospital and Karolinska Institutet. Molecular contraindications related to RAS mutations are evaluated using companion diagnostics originating from collaborations involving diagnostic manufacturers and laboratories at centers such as Mayo Clinic and Memorial Sloan Kettering Cancer Center. Precautionary measures for pulmonary, cardiac, and dermatologic risks align with recommendations from specialty societies including the American Thoracic Society and the European Society of Cardiology when managing complex patients.

Research and development history

Panitumumab's development involved biotechnology and pharmaceutical entities, academic laboratories, and funding agencies like the National Cancer Institute and venture collaborators seen in partnerships with companies analogous to Amgen and other industry sponsors. Early discovery research built on receptor biology pioneered by researchers associated with institutions such as Cold Spring Harbor Laboratory and Rockefeller University, while clinical development progressed through multicenter trials coordinated with cooperative groups including the European Organisation for Research and Treatment of Cancer and trial networks linked to National Institutes of Health programs. Regulatory milestones were achieved through submissions to the Food and Drug Administration and European Medicines Agency, and ongoing research explores combinations and biomarkers in academic consortia and translational centers like the Broad Institute and Dana-Farber Cancer Institute.

Category:Monoclonal antibodies